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In 1969 Li and Fraumeni identified, from a systematic study of
648 children with rhabdomyosarcomas, five families in which a
sibling or a cousin was affected by sarcoma (Li and Fraumeni,
1969a, b). A prospective study offour ofthe original families indi-
cated that there was a significantly increased risk ofcancer within
these families, particularly premenopausal breast cancer, as well as
a significant excess of second malignancies (Li and Fraumeni,
1982). The term 'Li-Fraumeni syndrome' was used initially by
Pearson et al (1982) and is now the most common term for this
dominant inherited cancer syndrome. Studies from our own group
on a population-based series of children with soft-tissue sarcoma
(Birch et al, 1984; 1990) and a USA hospital-based series of
survivors ofchildhood soft-tissue sarcomas from Strong's group in
the USA (Strong et al, 1987) confirmed that the familial clustering
was due to inherited predisposition and not to environmental
factors. Twenty-four families, defined using strict criteria, were
subsequently studied by the Li and Fraumeni groups (Li et al,
1988). Such families are now regarded as having 'classic'
Li-Fraumeni syndrome (LFS), namely a proband aged under 45
years with a sarcoma having a first-degree relative aged under 45
years with any cancer and an additional first- or second-degree
relative aged under45 years in the same lineage with any cancer or
a sarcoma at any age (Li et al, 1988). This study by Li et al (1988)
indicated that the spectrum of tumours within the syndrome
included acute leukaemia, premenopausal breast carcinoma, brain
and adrenocortical tumours as well as bone and soft-tissue
sarcomas. Other studies have indicated that a number of other
cancers may occur at an increased frequency in these families,
notably melanoma, germ cell tumours, Wilms' tumours, gastric
and pancreatic carcinomas and lung cancer (Hartley et al, 1987;
1989; Strong et al, 1987; Varley et al, 1995; 1997a).
While the definition of classic LFS has become generally
accepted, a number of groups have relaxed the description to
include incomplete Li-Fraumeni syndrome (a proband with an
affected first-degree relative; Brugieres et al, 1993) and Li-
Fraumeni-like syndrome (LFL). Two groups have defined LFL
families independently but using different criteria. Eeles (1995)
defined LFL as a clustering oftwo different tumours (both charac-
teristic of LFS) in individuals who are first- or second-degree
relatives of any age. Our own group has defined LFL by more
stringent criteria: a proband with any childhood tumour or
sarcoma, brain tumour or adrenocortical tumour under 45 years
plus a first- or second-degree relative with a typical LFS tumour at
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any age and another first- or second-degree relative with any
cancer under the age of 60 (Birch et al, 1994a). In the following
discussions, we refer to LFL families using the definition ofBirch
et al (1994a).
The rarity ofclassic LFS families plus the high mortality within
those families precluded a linkage study to identify the likely
chromosomal location ofthe causative genetic defect. Malkin et al
(1990) therefore adopted a candidate gene approach and analysed
the tumour-suppressor gene TP53. This gene was chosen because
mutations within TP53 had been identified in many tumour
types, including those commonly associated with Li-Fraumeni
syndrome. In addition, studies from transgenic mouse models had
indicated that germline mutation to TP53 was associated with an
elevated incidence of sarcomas, lymphoid malignancies, lung and
adrenal tumours (Lavigueur et al, 1989). In their original report,
Malkin et al (1990) studied five LFS families, all of whose
members had mutations within the TP53 gene.
THE TP53 GENE
TP53 was first identified in 1979 as a gene encoding a protein that
complexes to the large T antigen of SV40 (Lane and Crawford,
1979; Linzer and Levine, 1979). A number of properties initially
assigned to the TP53 protein, including the ability to immortalize
cells (Jenkins et al, 1984) and to transform primary rat embryo
fibroblasts in cooperation with ras (Eliyahu et al, 1984; Parada et
al, 1984), indicated that it was a dominantly acting oncogene.
Mutation to TP53 was found to enhance its transformation effi-
ciency, a finding compatible with the hypothesis that TP53 is a
cellular oncogene that can be activated by mutation (Jenkins et al,
1985). However, a number of observations indicated that the
'wild-type' TP53 proteins that had the properties of oncogenes
were in fact mutant, and more detailed studies showed that the
wild-type protein could not cooperate with ras, and indeed could
actually suppress transformation by mutant TP53 and ras (Finlay
et al, 1989). Furthermore, TP53 was shown to be lost or inacti-
vated in a number ofmalignancies, both human and murine, and is
now known to be the most frequently altered gene in human
tumours (Hollstein et al, 1991; Levine et al, 1991). There are
currently over4500 reports ofsomatic mutation in TP53 in human
tumours (Hollstein et al, 1996) and, although the mutations spread
over essentially the entire gene, there is considerable clustering of
mutations within the central region ofthe protein. The majority of
mutations are missense, with alterations at only five codons repre-
senting 25% of all known mutations (codons 175, 245, 248, 249
and 273; Hollstein et al, 1996).
TP53 is now known to possess a spectrum of properties,
including transcriptional activation and repression via sequence-
specific DNA binding to specific target sequences. Sequences at
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Table 1 Details of germline TP53 mutations reported in the literature
Codon Exon Mutation Typea Type of familyb Reference Loss of heterozygosity (LOH)
220 6 TAT-*TGT Tyr-4Cys
175 5 CGC-*CAC Arg-4His
248
248
248
108-111
180
136
191
248
344
273
245
273
175
Exon 1
Intron 3
Exon 4
209
248
213
275
248
Intron 4
273
175
193
7
7
7
4
5
5
6
7
10
8
7
8
5
1
4
6
7
6
8
7
8
5
6
CGG-*CAG Arg-*Gln
CGG-*CAG Arg-*Gln
CGG-JGG Arg-4Trp
Complex deletion-insertion
GAG-AAG Glu-*Lys
CAA-TAA Gln-*Stop
2-bp Deletion prem stop
CGG-4CAG Arg-*Gln
CTG-*CCG Leu-*Pro
CGT-*CAT Arg-4His
GGC-*AGC Gly-*Ser
CGT-TGT Arg-4Cys
CGC-*CAC Arg-*His
167-bp Deletion
Splice acceptor ag/Tf-aa/T
Splice donor CG/g-*CA/g
AGA-*TGA Arg-*Stop
CGG-*CAG Arg-*Gln
CGA-TGA Arg-+Stop
TGT-TAT Cys-Jyr
CGG-oCAG Arg-*Gln
Splice donor gt-oat
CGT-TGT Arg-oCys
CGC->CAC Arg-*His
CAT->CGT His-Arg
215 6 1-bp deletion leading to stop
Exon 10 10 Complex deletion of
248 7 CGG-*TGG Arg-Trp
258 7 GAA-*AAA Glu-*Lys
245 7 GGC-TGC Gly-*Cys
248 7 CGG-TGG Arg-4Trp
252 7 CTC-*CCC Leu-*Pro
248 7 CGG->CAG Arg-*Gln
241 7 TCC-TTC Ser-*Phe
245 7 GGC-4AGC Gly-*Ser
151-152 5 1-bp Insertion stop at 180
209-210 6 2-bp Deletion stop at 214
71-72 4 1-bp Insertion stop at 148
120 4 MG-JAG Lys-*Stop
282 8 CGG-TGG Arg-Trp
245 7 GGC->AGC Gly-*Ser
273 8 CGT-TGT Arg->Cys
267 8 CGG-*CAG Arg-*Gln
245 7 GGC->GAC Gly-Asp
242 7 CGT-4CAT Cys-*Tyr
248 7 CGG-TGG Arg-+Trp
282 8 CGG-*TGG Arg-*Trp
273 8 CGT-*CAT Arg-*His
325 9 GGA-*GTA Gly-Val
Intron 5 Splicing mutation 11bp del
273 8 CGT-4CAT Arg-*His
248 7 CGG-*TGG Arg-*Trp
273 8 CGT--GGT Arg-4Gly
282 8 CGG-TGG Arg-Trp
133 5 ATG-ACG Met-Thr
215 6 1-bp Deletion prem stop 246
257 7 CTG-*CAG Leu->Gln
257 7 1-bp Deletion prem stop
Exon 4 4 Splice donorCG/g->CA/g
196 6 CGA-4TGAArg->Stop
152 5 CCG-CTG Pro-4Leu
219 6 CCCO-TCC Pro-4Ser
235 7 MC-*GAC Asn-+Asp
175 5 CGC-+CAC Arg-*His
305 8 AAG-ATG Lys--Met
175 5 CGC-*CAC Arg-*His
272 8 GTG-*GCG Val-Ala
T LFS
CpG LFS
CpG
CpG
CpG
Del/ins
T
T
Del
CpG
T
CpG
CpG
CpG
CpG
Del
T
CpG
V
CpG
CpG
T
CpG
T
CpG
CpG
T
LFS
LFS
LFS
LFS
LFL
LFS
LFL
LFS
LFS
LFL
LFL
LFS
LFS
LFS
LFS
LFS
LFS
LFS
LFS
LFS
LFS
LFS
LFS
LFS
LFS
Del LFS
Del
CpG
T
V
CpG
T
CpG
T
CpG
Ins
Del
Ins
V
CpG
CpG
CpG
CpG
T
CpG
CpG
CpG
CpG
V
Del
CpG
CpG
V
CpG
T
Del LFS
V
Del
CpG
CpG
CpG
T
T
CpG
V
CpG
T
LFS
LFS
LFS
LFS
LFL
LFS
NFH
NFH (new mutation)
FH
LFS
LFS
FH
FH
LFL
LFL
LFL
FH
LFS
LFL
FH
FH
NFH
NFH
NFH
LFS?
FH
LFS
FH
LFS
FH
LFL
LFL
FH
FH
NFH
NFH
NFH
NFH
NFH
Same patient as above
Birch et al (1994a)
Birch et al (1994a)
Birch et al (1994a)
Birch et al (1994a)
Birch et al (1994a)
Birch et al (1994a)
Birch et al (1994a)
Varley et al (1997a)
Varley et al (1996)
Varley et al (1997a)
Varley et al (1996)
Varley et al (1997a)
Varley et al (1997a)
Varley et al (1997a)
Varley et al (1997a)
Varley et al (1997a)
Varley et al (1997a)
Varley et al (1997a)
Varley et al (1997a)
Frebourg et al (1995)
Frebourg et al (1995)
Frebourg et al (1995)
Frebourg et al (1995)
Frebourg et al (1995)
Frebourg et al (1995)
Frebourg et al (1995)
Frebourg et al (1995)
Stolzenberg et al (1994)
Plummer et al (1994)
Malkin et al (1990)
Malkin et al (1990)
Malkin et al (1990)
Malkin et al (1990)
Malkin et al (1990)
Toguchida et al (1992)
Toguchida et al (1992)
Toguchida et al (1992)
Toguchida et al (1992)
Toguchida et al (1992)
Toguchida et al (1992)
Toguchida et al (1992)
Toguchida et al (1992)
MacGeoch et al (1995)
Eeles et al (1993)
Prosser et al (1992)
Srivastava et al (1990)
Metzger et al (1991)
Malkin et al (1992)
Malkin et al (1992)
Malkin et al (1992)
Malkin et al (1992)
Felix et al (1993)
Kovar et al (1992)
Brugieres et al (1993)
Brugieres et al (1993)
Brugieres et al (1993)
Law et al (1991)
Hamelin et al (1994)
Mazoyer et al (1994)
Mazoyer et al (1994)
Warneford et al (1992)
Grayson et al (1994)
Wagner et al (1994)
Wagner et al (1994)
Wagner et al (1994)
Kyritsis et al (1994)
Kyritsis et al (1994)
Kyritsis et al (1994)
Kyritsis et al (1994)
LOH in 1/2
No LOH in 3/4, LOH of mutant
allele 1/4
LOH in 1/4
LOH in 1/3
LOH in 1/3
LOH of mutant allele 1/1
LOH in 1/2
LOH in 5/6
No LOH in 3/3
LOH in 1/1
No LOH in 1/1
LOH in 1/1
LOH in 3/4
LOH in 1/1
LOH in 1/1
LOH in 1/1
LOH in 1/1
LOH 1/3, LOH of mutant allele in 1/3
No LOH at p53, LOH at YNZ22
LOH in 4/4
No LOH in 1/1
LOH in 1/1
LOH in 1/1
LOH in 1/1
No LOH in 1/1
LOH in 2/2
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Table 1 cont.
Codon Exon Mutation Typea Type of familyb Reference Loss of heterozygosity (LOH)
5
5
5
5
5
7
6
5
5
5
6
7
8
8
5
7
5
5
5
7
7
8
8
8
8
7
7
8
7
8
8
8
7
CGC-*CTC Arg-4Leu
GCC-4TCC Ala->Ser
ACC-*AAC Thr-Asn
CAG-AAG Gln-*Lys
AGG-*GGG Arg-*Gly
TCC-ACC Ser-4Thr
CGA-*TGA Arg--Stop
CGC-*CAC Arg->His
CGC-*CAC Arg-*His
TAC-*TGC Tyr-*Cys
AGA-TGA Arg-*Stop
TGC-*TAC Cys-Tyr
CGT-AGT Arg-*Ser
GAG-*GTG Glu-*Val
GGC--GTC Gly-Val
ACA-ATA Thr-*lle
CCC->TCC Pro-4Ser
CGC->TGC Arg-*Cys
CGC-*CAC Arg-1His
GGC-AGC Gly-*Ser
Splice donor ag/G-*cg/G
TGC->TAC Cys->Tyr
GTG-4TTG Val->Leu
GGG-*TGG Gly->Trp
CGG->TGG Arg->Trp
CGG-*TGG Arg->Trp
CGG->TGG Arg->Trp
AAC-AGC Asn-*Ser
CGA-*CCA Arg-*Pro
TCT-ACT Ser-Thr
1-bp Deletion prem stop
GAA-*GCA Glu-*Ala
CGT-4CAT Arg-*His
GGC-*AGC Gly-*Ser
236 7 Deletion of codon (del TAC)
215-218 6 AGT GTG-*AGT TGG TTG
Val-Trp Leu
248 7 CGG-*TGG Arg-Trp
251 7 ATC-*ATG lle--Met
233 7 CAC-*GAC His-*Asn
273 8 CGT-TGT Arg-*Cys
245 7 GGC-AGC Gly-*Ser
133 5 ATG-4ACG Met-Thr
82 4 CCG-4CTG Pro-*Leu
278 8 CCT--CTT Pro-*Leu
209 6 2-bp Deletion
V
V
V
V.
T
V
CpG
CpG
CpG
T
V
T
V
V
V
T
T
CpG
CpG
CpG
V
T
V
V
CpG
CpG
CpG
T
V
V
Del
V
CpG
CpG
NFH
LFL
FH
NFH
NFH
NFH
FH
NFH
LFS
FH
NFH
NFH
NFH
NFH
NFH?
NFH?
Del LFL
Del/ins
CpG
V
V
CpG
CpG
T
CpG
Kyritsis et al (1994)
Kyritsis et al (1994)
Kyritsis et al (1994)
Kyritsis et al (1994)
Kyritsis et al (1994)
Kyritsis et al (1994)
Horio et al (1994)
Mcintyre et al (1994)
Mcintyre et al (1994)
Mcintyre et al (1994)
Mcintyre et al (1994)
Mcintyre et al (1994)
Mcintyre et al (1994)
Mcintyre et al (1994)
Chen et al (1995)
Chen et al (1995)
NFH (new mutation)
FH
FH
FH
LFL
NFH
LFS
NFH
NFH
LFS
LFS
NFH
NFH
NFH
LFUS
LFL
LFS
FH?
LFS
FH
FH
NFH
FH
NFH
LFS
FH
T NFH
Del NFH
Gutierrez et al (1994)
Sidransky et al (1992)
Berresen et al (1992)
Borresen et al (1992)
Jolly et al (1994)
Russo et al (1994)
Felix et al (1992)
Chung et al (1991)
lavarone et al (1992)
Shiseki et al (1993)
Scott et al (1993)
Diller et al (1995)
Diller et al (1995)
Diller et al (1995)
Sameshima et al (1992)
Sameshima et al (1992)
Porter et al (1992)
Felix et al (1995)
Lubbe et al (1995)
Strauss et al (1995)
Bang et al (1995)
Li et al (1995)
Li et al (1995)
Li et al (1995)
Li et al (1995)
Shay et al (1995)
Sun et al (1996)
Speiser et al (1996)
Felix et al (1996)
LOH in 1/3
LOH in 1/1
Mutation at codon 280 in other allele
in tumour
LOH in 1/1
LOH in 1/1
LOH in 1/1
No LOH in 1/1
LOH in 1/1
LOH in 1/1
No LOH in 1/1
LOH in 1/1
No LOH in 2/2
LOH in 1/1
LOH in 3/4
LOH in 1/1
(No LOH, but not sure of significance
of mutation)
LOH in 5/7
aMutation type: CpG, transition at CpG; T, non-CpG transition; V, transversion; del/ins, deletion and/or insertion. bFamily history: LFS and LFL, classic
Li-Fraumeni syndrome and Li-Fraumeni-like respectively; see text for definition. FH, family history but not conforming to LFS or LFL, taken as the patient
having at least one first-degree relative with cancer at age under 60 years; NFH, no strong family history.
the amino-terminus of the protein have transactivation properties
when interacting with target sequences through specific DNA
interactions (Fields and Jang, 1990). Five highly conserved
domains have been identified through sequence comparison across
species (Soussi et al, 1990), and these have been termed domains
I-V. Conserved domain I is within the transactivation domain. The
central part of the protein (amino acids 100-293) encodes the
DNA-binding domain, which recognizes and binds a consensus
target sequence (El-Deiry et al, 1992). Conserved domains II-V all
reside within this core DNA-binding region. The crystal structure
ofthe core DNA-binding domain has been determined as a largeP-
sandwich acting as a scaffold for two large loops and a
loop-sheet-helix, which together make all the interactions with
DNA (Cho et al, 1994). Of tremendous interest from this study
was the observation that the loop domains overlap with the highly
conserved domains and that the majority of mutations in human
tumours fall within the three loop motifs. Three residues (K120,
C277 and R280) interact through hydrogen bonds with DNA bases
and five (K120, S241, R273, A276 and R283) interact with phos-
phate groups of the major groove. The arginine residue at codon
248 has four crucial interactions with phosphate groups along the
minor groove (Cho et al, 1994; Vogelstein and Kinzler, 1994;
Arrowsmith and Morin, 1996). Two classes of mutation are
predicted from knowledge of this structure (Cho et al, 1994).
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181
138
155
167
174
241
213
175
175
163
209
242
273
271
154
256
151
181
181
245
Intron 5
242
272
293
282
282
248
235
306
227
307
286
273
245
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Contact mutations affect residues that directly contact DNA,
including R248 and R273, which are among the most frequently
mutated residues. Structural mutations affect residues that do not
directly contact DNA but which stabilize the structure ofTP53, for
example R249 and R175, both of which connect two ofthe loops.
The C-terminal end of the core DNA-binding domain was
shown by Cho et al (1994) to extend from the major groove away
from the bulk of the DNA-binding domain. TP53 functions as a
tetramer, and residues 324-355 are responsible for oligomeriza-
tion. The structure of this domain has been deduced from nuclear
magnetic resonance (Clore et al, 1994) and X-ray crystallography
(Jeffrey et al, 1995) and reveals that the TP53 tetramer is actually
a dimer of dimers. This structure fits well the observation that the
TP53 binding consensus sequence is a pair of inverted repeats (El-
Deiry et al, 1992). Relatively few mutations have been seen in the
tetramerization domain, the majority of which lead to premature
termination of the protein (Hollstein et al, 1996).
The TP53 gene maps to chromosome 17pl3.1, spanning around
20 kilobase pairs (kb), and comprises 11 exons. The coding region
spans exons 2-11, with the core DNA-binding domain being
encoded by part of exon 4 through to exon 8. As most of the
somatic mutations have been found within this core domain, many
groups have only analysed exons 5-8 for point mutation. While
there is little doubt that mutations within these exons are the most
frequent, it has become difficult to assess the frequency of muta-
tions outside this region, and it has been estimated that over 20%
mutations remain undetected (Greenblatt et al, 1994).
In addition to the properties of TP53 described above, wild-type
TP53 has been termed the 'guardian of the genome' (Lane, 1992).
Wild-type TP53 functions in checkpoint control after DNA
damage (Kuerbitz et al, 1992), resulting in either a delay in cell
cycle progression at the G,/S border to allow DNA repair (Kastan
et al, 1991) or apoptosis (Yonish-Rouach et al, 1991). TP53 has
also been implicated directly in DNA repair (Ford and Hanawalt,
1995) and in GC arrest (Paules et al, 1995; Stewart et al, 1995).
The majority ofmutations described in other tumour-suppressor
genes such as RB], APC and BRCAI are clearly loss-of-function
mutations. The mutation spectrum in these genes shows a high
proportion of nonsense and frameshift mutations that produce an
absent or truncated protein. Mutations to TP53 are most frequently
missense and, while they may lead to loss ofcertain functions such
as failure to arrest in G,/S or G2, they frequently result in the gain
of a function such as the ability to cooperate with ras in the
transformation of fibroblasts. In addition, certain TP53 mutants
may demonstrate a dominant-negative function by, for example,
forming oligomeric complexes with wild-type TP53 and blocking
its normal functions (Milner and Metcalf, 1991).
The relatively bewildering spectrum of mutations seen in human
tumours coupled to some understanding of the functions of various
domains of the TP53 protein has led a number of groups to estab-
lish assays to evaluate the relevance of mutations. Many assays are
available, including growth arrest oftarget cells, apoptosis or trans-
activation of target genes in mammalian cells. Perhaps the most
useful assays, and the ones which have additionally been used as a
screen to detect the presence of TP53 mutations in both human
tumours and the germline, are functional assays in yeast. Initially
the assay, based on the inability of the majority of TP53 mutants
to transactivate target genes, was established in human cells
(Frebourg et al, 1992). However with the demonstration that
mammalian TP53 can function in yeast cells (Scharer and Iggo,
1992), a simple functional assay was described (Ishioka et al, 1993;
Flaman et al, 1995). This assay will now provide a mechanism by
which mutations can be assessed for their transactivation proper-
ties. As yet, relatively few mutations have been assessed in this
yeast assay, but not all mutations will be detected. The assay relies
on high-quality mRNA from the test source, which is reverse-tran-
scribed into cDNA and integrated into a yeast plasmid by homolo-
gous recombination in vivo. Codons 67-347 are integrated into the
yeast plasmid, therefore any mutations outside these regions will
not be detected. In addition, large deletions or insertions may not be
detected and nor will any mutations in which there is little or no
expression ofthe mutant transcript (Flaman et al, 1995).
TP53 MUTATIONS AND LI-FRAUMENI FAMILIES
In the initial study describing the involvement of germline TP53
mutations in LFS, Malkin et al (1990) studied five Li-Fraumeni
families and sequenced exons 5-8 in affected individuals from
each family. All five families had missense mutations, all within
the highly conserved region IV of exon 7. The clustering of muta-
tions within this short region of the protein was confirmed in a
further family (Srivastava et al, 1990), leading to the proposal that
there was a restriction upon the mutations in the TP53 gene that are
permitted in the germline (Vogelstein, 1990). However, analysis of
eight classic LFS families by Santibanez-Koref et al (1991)
revealed that mutations in exon 7 only occurred in two families,
and subsequently mutations have been found throughout the gene
(see below). Although TP53 mutations have been reported in over
50 Li-Fraumeni families (see Table 1), only two studies have
analysed consecutively ascertained series of such families.
Frebourg et al (1995) have studied 15 families conforming to
classic LFS and have identified eight families with germline muta-
tions by screening exons 2- 11. Recent data from our own studies
(Varley et al, 1997a), in which all 11 exons plus the promoter
region and all splice junctions have been analysed by direct
sequencing, has identified 15 germline TP53 mutations in 21 LFS
families (71%) and four mutations in 18 LFL families. From these
two studies, it is clear that germline mutations within the coding
regions of TP53 are not responsible for all Li-Fraumeni families.
GERMLINE TP53 MUTATIONS IN PATIENTS
WITH TUMOURS TYPICAL OF LFS
Since the original description of germline TP53 mutations, there
have been a number of studies in which series of patients with
tumours characteristic of Li-Fraumeni syndrome have been
screened to determine the proportion ofthose patients who are gene
carriers (see Table 1). Patients with bone or soft-tissue sarcomas
were studied by Toguchida et al (1992), including 181 cases of
sporadic disease and 15 patients with an unusual family history of
cancer or multiple primary tumours. Three TP53 germline muta-
tions were detected in the former group, but all were subsequently
found to have multiple primary tumours or first-degree relatives
with sarcomas. In the group that had been selected, five germline
mutations were found (33%), indicating that up to one-third of the
patients with sarcoma and either multiple tumours or an unusual
family history were carriers of germline TP53 mutations. McIntyre
et al (1994) studied 237 unselected children with osteosarcoma and
found seven with a germline mutation; Porter et al (1992) reported
one germline mutations out of seventeen patients with osteosar-
coma and lavarone et al (1992) reported one germline mutation in
four patients with multifocal osteogenic sarcoma. Diller et al
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(1995) examined 33 patients with childhood rhabdomyosarcoma
and found three germline mutations, all in the group of 13 children
under the age ofthree (23%). Clearly it is now possible to identify a
group of affected individuals with sarcoma at high risk of carrying
a germline TP53 mutation. The occurrence of sarcomas (particu-
larly rhabdomyosarcomas) in young children, an unusual family
history or multiple primary tumours should warrant an examination
for a germline TP53 mutation. From studies already published, it
appears that up to one-third ofthis group may be carriers.
A number of studies have also been carried out on patients with
brain tumours. Kyritsis et al (1994) found TP53 mutations in nine
of 51 patients with glioma, all of whom had either multifocal
disease or a family history of cancer. Other studies have found
germline TP53 mutations in around 2-10% of cases of brain
tumour, with the highest frequency in gliomas in children or young
adults with an unusual personal or family history ofcancer (Chung
et al, 1991; Chen et al, 1995; Felix et al, 1995; Li et al, 1995).
Premenopausal breast cancer is very common in Li-Fraumeni
families, and three groups have examined series of sporadic breast
cancerpatients for germline TP53 mutations (B0rresen et al, 1992;
Prosser et al, 1992; Sidransky et al, 1992). Only four mutations
were detected in a total of 499 patients studied by these three
groups, indicating that TP53 mutations are responsible for no
more than 1% of breast tumours. All four patients showed very
strong family histories ofcancer. Although frequently overlooked,
patients with germline TP53 mutations contribute significantly to
the number of breast cancer cases with a strong inherited compo-
nent, particularly when breast cancer is diagnosed at a very young
age (< 30 years). It has been estimated that around 1% of breast
cancer cases between the ages of 30 and 40 years arise within
Li-Fraumeni families (Easton et al, 1993). This is clearly lower
than the proportion ofearly-onset cancers due to either BRCAI or
BRCA2 but is nonetheless significant.
Wagner et al (1994) examined children with adrenocortical
carcinoma (ACC) and, although the numbers are small, three ofsix
had germline TP53 mutations. Selection of families on the basis
of an ACC also indicated a very high frequency of mutations
(Sameshima et al, 1992). In the Li-Fraumeni families that we have
studied to date, all five in which there is an adrenocortical tumour
have a germline TP53 mutation, and there are no cases of ACC in
any negative family (Varley et al, 1997a).
Finally, studies of patients selected on the basis of multiple
primary tumours (Malkin et al, 1992; Shiseki et al, 1993; Russo et
al, 1994) have shown that they have germline TP53 mutations at a
frequency ofbetween 7% and 20%.
Although Li-Fraumeni families are rare, nonetheless germline
TP53 mutations are frequent in individuals with specific cancers,
particularly at young age. Half of all cases of childhood ACC and
between one-quarter and one-third ofchildhood sarcomas, particu-
larly multifocal or with a family history, arise in patients with a
germline TP53 mutation. Any patient presenting with such
tumours, especially ifthere is additional personal or family history
ofmalignancy, should be considered as apotential mutation carrier.
This could have profound implications forboth the treatment ofthe
patients and their subsequent monitoring and for analysing TP53
for mutation with a view to offering other family members predic-
tive tests. This will be discussed in more detail later in this review.
It should also be noted that in the majority of studies cited above,
analysis of TP53 has not covered the entire coding region and, if
this were carried out, the frequency of germline mutations within
various groups ofcancer patients may rise.
THE SPECTRUM AND TYPE OF GERMLINE TP53
MUTATIONS
There are now over 50 families reported that conform to the defin-
ition of classic LFS or LFL, using the definition of Birch et al
(1994a), and in whose members germline TP53 mutations have
been found (Table 1). From the literature, the proportion of fami-
lies that do not have a detectable coding mutation is not generally
clear. There have been only two studies in which there has been a
systematic analysis of TP53 in series of families (Birch et al,
1994a; Frebourg et al, 1995; Varley et al, 1997a), and both ofthese
studies have identified families in which there is no coding muta-
tion. Frebourg et al (1995) found 7 of 15 LFS families to have no
mutation, although they did not examine exon or the promoter
region. In our own series (Varley et al, 1997a), we found mutations
in 71% ofclassic LFS families. There are many reports in the liter-
ature of single families in which a mutation has been found, but it
is not possible to determine how many families have been exam-
ined and found to be negative; however, it seems likely that at least
30% of LFS families have no coding mutation. There is only one
definite report of a Li-Fraumeni family in which the syndrome
was unlinked to TP53 (Birch et al, 1994b), although normal tissues
from affected individuals within this family have been shown to
express elevated levels of TP53. The only other family in which
there appeared to be no TP53 mutation but overexpression in
normal tissues (Barnes et al, 1992) has been subsequently shown
to have a mutation in the tetramerization domain encoded by exon
10 (Lomax et al, 1997). There have been reports that in some
negative families the expression of TP53 is limited to one allele,
implicating a possible regulatory mutation in some Li-Fraumeni
families (Li and Fraumeni, 1994).
We are aware of 114 reports of germline TP53 mutations (see
Table 1), ascertained by analysis of LFS or LFL families, as well
as others such as breast (B0rresen et al, 1992; Prosser et al, 1992;
Jolly et al, 1994; Shay et al, 1995; Sun et al, 1996) or brain (Lubbe
et al, 1995) site-specific families or cohorts of patients with
tumours typical of Li-Fraumeni syndrome (see above). The spec-
trum of mutations shows that the majority of all germline muta-
tions cluster in exons 5-8, however this is undoubtedly skewed
because most studies only examine these exons. In our own study,
of 19 mutations found to date, five fall outside these exons (26%;
Varley et al, 1997a). This finding has profound implications for
genetic testing within Li-Fraumeni families, and we recommend
that all exons, both coding and non-coding, plus all splice junc-
tions and the promoter region are analysed.
We have analysed all the reported germline mutations to deter-
mine the mutation type. There is no difference in the frequency of
missense and nonsense mutations between Li-Fraumeni families,
other types of families and individuals with no family history. In
addition, there are no differences between LFS and LFL families.
There are two reports oflarge germline deletions, one involving
the whole of exon 10 (Plummer et al, 1994) and the other
removing 167 bp, including part of exon 1 and intron 1 (Varley et
al, 1997a). Both of these deletions were flanked by short direct
repeat sequences. Thirteen other mutations involve short insertion
or deletion events (Sameshima et al, 1992; Toguchida et al, 1992;
Felix et al, 1993; Birch et al, 1994a; Hamelin et al, 1994; Mazoyer
et al, 1994; Stolzenberg et al, 1994; Lubbe et al, 1995; Strauss et
al, 1995; Felix et al, 1996; Varley et al, 1996a, 1997a). All ofthese
events occurred where there were runs of two or more identical
bases or short repeated motifs, except in one case (Mazoyer et al,
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1994). Although deletions and insertions are most frequent in
exons 2-4 and 9-11 in sporadic tumours (Harris, 1996), in the 114
germline mutations we have reviewed, the situation is not as
straightforward. There is only one report of a mutation in exon I
(Varley et al, 1997a), which is a large deletion, and there are no
reported mutations in exons 2 and 3. Two of the six mutations in
exon 4 are deletions or insertions. One of the three mutations
reported in exons 9-11 is a large deletion (Plummer et al, 1994).
Deletions or insertions therefore constitute a significant proportion
of the mutations in exons 1-4 and 9-11 in germline tumours, as
seen in sporadic tumours. However, six of the 14 mutations
reported in exon 6 are deletions or insertions at short repeat
sequences, with all except one leading to a frameshift and prema-
ture termination. Harris (1996) suggests that deletions or inser-
tions in sporadic tumours are more frequent in exons 2-4 and 9-11
because the regions of the TP53 protein encoded by these exons
generally require more than one mutation to abrogate function, and
this is most efficiently caused by a deletion or insertion event.
Why these events are seen at such a high frequency in exon 6 as
germline mutations is unclear at present. Thirteen of the 15 dele-
tion or insertion events were found in patients with a strong family
history, twelve with family histories compatible with Li-Fraumeni
syndrome (see Table 1).
In all reports of germline TP53 mutations, transitions are the
most common change, accounting for 66% of all germline muta-
tions, with those within CpGs being the predominant type (44% of
all mutations). These types ofmutation are considered to represent
endogenous events. Cytosine and 5-methylcytosine can sponta-
neously deaminate to uracil and thymine, respectively, resulting in
G:C to A:T transitions. The majority of transitions occur at CpG
dinucleotides, which are common sites for methylation, and transi-
tions can also occur as a result of replication errors. When the
frequency of transitions in patients with any family history of
cancer is compared with that in patients with no family history,
there is an under-representation of transitions at CpG in the latter
group (P < 0.004). In this and subsequent analyses, we scored
patients as having a family history if they had at least one first-
degree relative with cancer under the age of60 years or ifthey had
a family history compatible with LFS or LFL. There was no differ-
ence in the frequency oftransitions between patients with a family
history compatible with LFS or LFL and all other patients with or
without a family history.
Transversions represent 21% of all germline mutations.
Transversions can occur as a result of replication errors but are
also considered to represent the possibility of exogenous carcino-
genic insult. G residues are a common target forbulky carcinogen-
induced adducts, resulting in stalling of the replication machinery
and misincorporation by DNA polymerase. We therefore analysed
the data on the 114 germline mutations to determine whether there
was a difference between the frequency of transversions in
patients with a strong family history and those without a family
history. Whereas only 11 transversions were seen in 81 cases
(14%) when there was a strong family history, 13 of the other 33
cases (without a family history) had transversion mutations (39%).
This difference is statistically significant (P < 0.005) and raises the
possibility that the majority ofgermline mutations that have arisen
recently may be due to exposure to carcinogens. A more detailed
collaborative epidemiological study would be required to address
this possibility. Intriguingly, when patients with germline muta-
tions are separated into LFS or LFL family members vs others
(both with and without a family history), the difference in the
frequency oftransversions is still significantly different (P < 0.02),
and an increased occurrence of deletions or insertions in LFS or
LFL families reaches significance (P < 0.03).
GENOTYPE-PHENOTYPE CORRELATIONS AND
PENETRANCE
The finding that around 30% ofclassic LFS families and a higher
percentage of LFL families have no TP53 coding mutation raises
the question as to whether there may be phenotypic differences
between those families with and those without identifiable muta-
tions. Although there are numerous reports of individual families
or patients, or groups offamilies and patients, with germline TP53
mutations, there are only two published series offamilies in whom
the entire coding sequence ofTP53 has been analysed (Frebourg et
al, 1995; Varley et al, 1997a), with only the latter study including
an analysis ofexon 1 and the promoter region. Furthermore, in the
study by Frebourg et al (1995), details ofthe pedigrees ofthe fami-
lies included in the study were not published. The only series in
which it is possible to analyse the cancer phenotype in LFS and
LFL families with and without germline TP53 mutations is that
assembled by our own group. In 30 of the families in whom
sequence analysis ofthe entire TP53 gene has been completed (18
LFS and 12 LFL), histopathological review of tumours has been
carried out. The distribution ofcancers by morphological type and
age at diagnosis has been analysed in these families. The analysis
included cancers in the probands and theirfirst- and second-degree
relatives. Twelve of the 18 LFS and four of the 12 LFL families
carried germline TP53 mutations. In these 16 families, mutation
status was determined in as many family members as possible, but
all cancers in eligible relatives as defined above were included in
the analysis, regardless ofwhether or not mutation status had been
determined in the individual concerned. This strategy ensured
comparability between the mutation-positive and -negative fami-
lies. In total, 116 cancers in LFS and LFL families have been
included in the analysis (Table 2).
When the distribution of cancer cases in the 30 LFS and LFL
families overall is analysed, there was a higher proportion of
sarcomas in LFS families, but this can be attributed to the require-
ment of the classic LFS criteria for a proband with sarcoma. If
sarcomas are excluded, then the distribution of first primary
Table 2 Spectrum and distribution of cancers in LFS and LFL families with
and without germline TP53 mutations
Tumour type TP53 positive TP53 negative Total
Soft-tissue sarcomaa 13 (19.1) 10 (20.8) 23 (19.8)
Bonea 7 (10.3) 5 (10.4) 12 (10.3)
Breastb 19 (27.9) 13 (27.1) 32 (27.6)
Brain 13 (19.1) 3 (6.3) 16 (13.8)
Leukaemia/lymphoma 1 (1.5) 5 (10.4) 6 (5.2)
Adrenocortical 5 (7.4) 0 5 (4.3)
Digestive system 7 (10.3) 6 (12.5) 13 (11.2)
Genitourinary system 1 (1.5) 4 (8.3) 5 (4.3)
Lung 2 (2.9) 2 (4.2) 4 (3.5)
Total 68 (100) 48 (100) 116 (100)
aEighty-five per cent of sarcomas (soft tissue plus bone) in TP53-positive
families occurred under the age of 20 years compared with 50% of those in
TP53-negative families. bSeventy-nine per cent of breast cancers in TP53-
positive families occurred under the age of 40 years compared with 39% in
TP53-negative families. Numbers in parentheses are percentages.
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tumours in LFS and LFL families is very similar. In LFS families,
40% of the non-sarcoma cancers were carcinomas of the breast
compared with 39% in LFL families; the figures for brain tumours
were 18% and 22% respectively. In both sets of families, the age
distribution at diagnosis of cancer was strikingly young. In LFS
families, 56% of the cancer cases were diagnosed under age 30
years and 100% under age 50 years; in LFL families the figures
were 44% and 78% respectively. In the general population, only 2%
ofcancer cases occur under 30 years ofage and 11% under 50 years
of age (data derived from cancer registrations for England and
Wales, 1991, Office ofNational Statistics, September 1996).
When the two sets of families were divided on the basis of the
presence or absence of a germline TP53 mutation, it was found that
overall the cancer cases in families with germline TP53 mutations
had a somewhat earlier age of onset, but this was not particularly
marked (median age of onset of cancer in LFS and LFL families
with germline TP53 mutations is 27 years and in those without
mutations is 31 years). The proportions of sarcomas and breast
cancers in the TP53-positive and -negative families are very similar
(sarcomas in positive vs negative families is 29% vs 31%, respec-
tively, and breast cancers 28% vs 27% respectively; see Table 2).
However, the age distributions ofthese cancer cases in the two sets
offamilies did differ. Thus 85% ofsoft tissue sarcomas in mutation-
positive families were diagnosed when the individual was under 20
years of age compared with 50% in the mutation-negative families.
For breast cancer, 79% were diagnosed under 40 years in the muta-
tion-positive families compared with 39% in the negative families.
Considering other types of cancers, there was a distinct excess
ofbrain tumours in the TP53-positive families, 19% ofall cancers
in the mutation-positive families were brain tumours compared
with only 6% in the negative families, and 81% of all brain
tumours in the entire series of families occur in those with
germline TP53 mutations. All five adrenocortical tumours in the
series occurred in families with mutations. However, there
appeared to be a deficit of leukaemias and lymphomas in the
mutation-positive families, with less than 2% of the cancers in
these families being of these types compared with 10% in the
mutation-negative families.
The above analyses were based on first primary cancers only.
The occurrence of multiple primary cancers in members of
Li-Fraumeni families is well described, and there was a similar
proportion of individuals with second and subsequent primary
tumours in the TP53 mutation-positive and -negative families.
However, in the mutation-positive families sarcoma was the most
common second primary, whereas in the negative families breast
cancer was the most common.
The data reported above are incomplete as diagnostic review of
cancers in the entire series offamilies is still in progress. However,
on the basis of these preliminary analyses there do appear to be
phenotypic differences between Li-Fraumeni families with and
without germline TP53 mutations. 'Marker' cancers for the pres-
ence ofsuch mutations in both LFS and LFL families appear to be
early-onset soft-tissue sarcoma, in particular rhabdomyosarcoma
diagnosed under the median age of diagnosis for all childhood
rhabdomyosarcomas (under 4 years), adrenocortical carcinoma,
breast cancer aged under 40 years, and brain tumours in children
and young adults. Histological examination of the CNS tumours
that occurred in carriers of TP53 germline mutations in our series
showed them to be mainly high-grade astrocytoma orglioblastoma
and childhood medulloblastoma. Results of the formal analysis of
cancer phenotype in the entire series of families examined by us
may have important implications for counselling and future
screening regimens in families both with and without germline
TP53 mutations.
In those families with germline TP53 mutations, it will also be
important in relation to genetic counselling and disease screening
to have reliable estimates of penetrance and age-specific risks for
the various component cancers of the syndrome. At present, there
are insufficient data to provide such estimates. However, prelimi-
nary data do exist that could provide some guidance. On the basis
of population studies of cancer risks in families of children with
sarcoma and follow-up studies in families with LFS, it has been
shown that the risk ofcancer is elevated up to, but not beyond, age
60 years (Birch et al, 1990; Garber et al, 1991). Using a data set
comprising details of occurrence of cancer among the close
relatives of a hospital-based series of children who had survived
sarcoma, Lustbader et al (1992) conducted a segregation analysis.
This demonstrated that the distribution of cancer in the families
was consistent with a rare autosomal dominant gene (frequency
0.00002) with penetrance of approximately 50% by age 40 years
and up to 90% by age 60 years. The age-specific penetrance was
higher in women than in men because ofbreast cancer occurrence.
It is likely that the major component of the familial cancer clus-
tering detected by Lustbader et al (1992) was due to TP53 but
there is a possibility that other genes such as BRCA2 and NFI may
be making small contributions. This should be borne in mind when
interpreting these results.
The only published estimates of age-specific risks associated
with germline TP53 mutations were based on only five families
but used a new method which addresses the problem of ascertain-
ment bias (LeBihan et al, 1995). Risks were estimated to be 42%
between ages 0 and 16 years, 38% between ages 17 and 45 years
and 63% after age 45 years; lifetime risk was estimated to be 85%
(LeBihan et al, 1995). Although these results should be viewed
with caution, because they are based on such small numbers, the
method should prove to be useful in analysing larger series. This
requires international collaboration, and such a study is planned.
LOSS OF HETEROZYGOSITY STUDIES IN
TUMOURS FROM PATIENTS WITH GERMLINE
TP53 MUTATIONS
Wild-type TP53 is considered to be a tumour-suppressor gene
(Hollstein et al, 1991; Levine et al, 1991; Lane, 1992) and as such
a number of tumours of a variety of types from patients with
germline TP53 mutations have been analysed for loss ofheterozy-
gosity (LOH). LOH at a particular locus/gene is considered to indi-
cate the presence of a tumour suppressor at that locus (Ponder,
1988), with the LOH event unmasking the recessive mutation.
Tumour-suppressor genes such as BRCAJ (Smith et al, 1992), RBI
(Cavenee et al, 1983), BRCA2 (Gudmundsson et al, 1995), APC
(Ichii et al, 1992) and VHL (Tory et al, 1989) have been studied in
many families in which there is a germline mutation to those
genes, and loss of the wild-type allele has been seen at high
frequency in the tumours of patients carrying the mutation. All
these genes therefore fulfil the criteria expected of tumour-
suppressor genes, namely obeying Knudson's 'two-hit' hypothesis
(Knudson, 1971), whereby one defective allele is inherited and
the second is inactivated by loss of part or all of the wild-type
chromosome (Ponder, 1988).
To our knowledge 82 tumours from patients with germline
mutations at TP53 have been studied for LOH, with LOH detected
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in 57% of those tumours (see Table 2; Varley et al, 1997b). This
figure is lower than expected from a comparison of the loss of
other tumour-suppressor genes in inherited cancer syndromes, in
which levels of 80% LOH are not unusual. However, only one
systematic study of LOH has been carried out in a large series of
patients with defined TP53 mutations in tumour material that has
been characterized according to current standard criteria (Varley et
al, 1997b); most other studies have involved examination of LOH
in a single family and/or a very few tumours. In the former study,
LOH was observed in only 44% of tumours, but a number of inter-
esting patterns of LOH were described. All tumours except breast
in which there was a codon 248 mutation showed retention of the
wild-type allele. Only one other tumour described in the literature
with a codon 248 mutation has been analysed for LOH and that
also failed to show LOH (Scott et al, 1993). This finding is
discussed in more detail in Varley et al (1997b), but it is not
obvious why there should be no loss of the wild-type allele in the
presence of a codon 248 mutation, whereas a variety of tumours
with a range of other mutations do show LOH. If tumours with
codon 248 mutations are excluded from the analysis, LOH is seen
in 60%, which is still lower than that seen for other tumour-
suppressor genes. However, it is possible that there is under-
reporting of LOH, with contamination of the tumour sample with
normal cells accounting for the number of cases in which there is
apparently no LOH. In the consecutive series in which all tumours
were assessed to ensure a high percentage of tumour cells before
analysis, LOH was also seen in only 60% of cases (excluding
those with a codon 248 mutation; Varley et al, 1997b). The figure
of 60% LOH is therefore consistent among the different studies
and reflects the true level of LOH.
LOH has been seen in a number of benign or premalignant
lesions, including ductal carcinoma in situ of the breast and
endometrial hyperplasia (Varley et al, 1996a) and an adreno-
cortical tumour (Varley et al, 1995). More surprisingly, loss of
the mutant allele has been seen in three cases (Eeles et al, 1993;
Varley et al, 1997b).
To date, of four reports in which LOH has been examined in
gastric/stomach tumours, all showed retention of the wild-type
allele (Scott et al, 1993; Horio et al, 1994; Varley et al, 1997b). In
contrast, of thirteen breast tumours studied, LOH was seen in ten
(Malkin et al, 1990; B0rresen et al, 1992; Prosser et al, 1992;
Srivastava et al, 1992; Warneford et al, 1992; Eeles et al, 1993;
Varley et al, 1997b). We have examined other markers on chromo-
some 17 in five breast tumours showing LOH at TP53 and have
demonstrated that the loss seen is not targeting more distal candi-
date tumour-suppressor loci on the short arm of chromosome 17
nor loci on the long arm (Varley et al, 1997b).
The relatively low level of LOH seen in tumours from patients
with germline TP53 mutations compared with the levels of loss
seen of other genes in inherited cancer syndromes is not entirely
surprising given the range of functions of TP53 as described
above. It could be considered that gain-of-function mutants or
those showing dominant-negative features may be sufficient to
induce tumour formation in the presence of the wild-type gene.
Why this should be so in tumours in patients with an inherited
mutation when the situation is different in sporadic tumours
remains unclear. Recent data from studies of TP53-deficient mice
demonstrate that 40-50% oftumours that develop in heterozygous
null mice do not show LOH and that the retained allele has the
properties ofwild-type TP53 (LA Donehower, personal communi-
cation; Shi et al, 1997).
FUNCTIONAL STUDIES OF LI-FRAUMENI CELLS
There have been many studies carried out to examine the altered
function(s) of the variety of TP53 mutations that occur in human
tumours. Many of these studies involve the introduction of mutant
TP53 constructs into cells that either contain an endogenous wild-
type TP53 gene or that are null for TP53. Frequently the mutant
TP53 gene is overexpressed, and a number of functional end
points are examined. These studies all suffer from a common
drawback: the genetic background in which the assays take place
does not reflect that of a normal cell from a patient with a germline
TPS3 mutation. For this reason, a number of groups have exam-
ined cells derived from patients with germline TP53 mutations,
most commonly lymphoblastoid or fibroblast cell lines.
Fibroblasts from Li-Fraumeni patients show chromosomal
sensitivity (measured by an increased frequency of chromosome
aberrations) to the effects of ionizing radiation (Parshad et al,
1993), in contrast to the cellular radioresistance (measured by cell
survival) observed by Bech-Hansen et al (1981) and our own group
(Sproston et al, 1996). Chromosomal radiosensitivity has also been
observed in lymphocytes from Li-Fraumeni patients (D Scott,
personal communication). While Li-Fraumeni fibroblasts show a
level of transient G, arrest that is indistinguishable from normal
cells, their permanentG, arrest is considerably reduced (Williams et
al, 1997). Permanent G, arrest in fibroblasts is considered to be the
functional equivalent of apoptosis in other cell types, in removing
cells that have received genetic damage. This hypothesis is
supported by the findings of Camplejohn et al (1995) that lympho-
cytes from Li-Fraumeni patients with a germline TP53 mutation
show an abnormal apoptotic response. The failure of Li-Fraumeni
fibroblasts to permanently arrest atGI may contribute towards the
predisposition ofheterozygous individuals to cancer.
The above studies were all carried out on relatively early-
passage heterozygous (i.e. wild type/mutant) fibroblasts that had
been treated with a DNA-damaging agent of some sort, usually
irradiation. However Li-Fraumeni fibroblasts that are maintained
in culture and not subjected to any damaging agents also show a
range of abnormalities. As they are cultured through progressive
population doublings, they show an increased number ofchromo-
some abnormalities of all types (Bischoff et al, 1990; Yin et al,
1992; Rogan et al, 1995), loss of the wild-type allele (Yin et al,
1992; Rogan et al, 1995), changes in morphology and, rarely,
spontaneous immortalization (Bischoff et al, 1990; Rogan et al,
1995) accompanied by telomere elongation (Rogan et al, 1995).
Spontaneous immortalization has also been reported in breast
epithelial cells from a LFS patient with a germline TP53 mutation
(Shay et al, 1995), and even Li-Fraumeni cells that fail to immor-
talize spontaneously can be induced to do so by treatment with
various agents that have no effect on normal cells (Shay et al,
1995; Tsutsui et al, 1995).
The loss ofwild-type TP53 from Li-Fraumeni fibroblasts corre-
lates in vitro with failure to arrest inGI when treated with a uridine
biosynthesis inhibitor PALA and subsequent PALA-selected gene
amplification (Livingstone et al, 1992; Yin et al, 1992). This
phenotype is reversible upon reintroducing a wild-type TP53
construct into the fibroblasts. PALA reduces the intracellular pool
of nucleotides, and inappropriate entry of cells into S-phase after
PALA treatment as aresult ofthe failure to arrest inG, could result
in chromosome breakage or fragmentation and could initiate gene
amplification (Yin et al, 1992), which is one manifestation of
genomic instability. PK Liu et al (1996) have examined other
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aspects ofgenomic instability in LFS fibroblast cells that are early
wild type/mutant or late passage (-/mutant). Interestingly in
fibroblasts that still retain the wild-type allele, there is a high level
ofpoint mutation within a reporterplasmid, and in fact this level is
higher than in those cells that have lost the wild-type allele. The
authors suggest that heterozygous LFS cells contain an activity (a
mutant TP53 gene) that promotes mutations, contributing towards
the genomic instability seen in these cells (PK Liu et al, 1996).
The demonstration of a failed G2 arrest in Li-Fraumeni fibro-
blasts (Paules et al, 1995) is further evidence of a failure to recog-
nize DNA damage. Even partial failure of a G2 checkpoint in
Li-Fraumeni cells would be sufficient to allow some damaged
cells to enter mitosis. As these cells could well have chromosome
damage, populations of chromosomally abnormal cells could
expand. The data obtained from the studies of human cells are
supported by observations on TP53-deficient mice. These mice
have defective G2 (Bouffler et al, 1995) and mitotic spindle check-
point control (Cross et al, 1995), leading to numerical chromo-
some changes (both aneuploidy and polyploidy). In summary,
Li-Fraumeni cells with a mutant TP53 gene have lost control at a
number of levels of genome surveillance. Not only has normal
TP53 function been lost in terms of transactivation, interaction
with other cellular proteins and DNA binding, but both key cell
cycle checkpoints are perturbed. The failure of Li-Fraumeni cells
carrying a germline TP53 defect to recognize DNA damage and to
arrest at either checkpoint, coupled with a potential 'mutator'
phenotype (PK Liu et al, 1996) will result in cells with a steadily
increasing burden of genetic damage. Whether the extent of these
phenotypic alterations is different in a variety ofcell types remains
to be investigated, but it could account for the tumour spectrum
seen in Li-Fraumeni families.
Studies using EBV-transformed lymphoblastoid cell lines
derived from patients with germline TP53 mutations have shown
that these cells behave in a manner indistinguishable from normal
cells. Lalle et al (1995) showed that the cells retained a normal
induction of p21wafl and MDM2 upon DNA damage and main-
tained genomic stability and that there was no loss ofthe wild-type
TP53 allele in heterozygous cells even after 1 year in culture.
Williams et al (1996) showed that the presence of a heterozygous
TP53 mutation had no effect on TP53 expression after DNA
damage or on G,/S arrest. There are clearly differences in the
phenotype of unstimulated lymphocytes from patients with
germline TP53 mutations, such as an abnormal apoptotic response
(Camplejohn et al, 1995), and it is possible that the immortaliza-
tion by EBV is influencing the behaviour ofthese cells in a TP53-
independent manner. However, the data may also suggest that the
different tissue-specific phenotypic responses to the presence of a
heterozygous TP53 mutation could account for the spectrum of
tumour types observed in patients from Li-Fraumeni families
(Lalle et al, 1995; Williams et al, 1996).
To summarize all the data obtained from many different studies,
the presence of a germline TP53 mutation in the heterozygous
state appears to permit the accumulation of genetic damage,
leading to genomic instability and eventually neoplastic transfor-
mation. However, although a range of tumour types is seen in
Li-Fraumeni families, many common solid tumours are not repre-
sented to a significant degree (e.g. colorectal tumours and gynae-
cological malignancies), and the reason for the limited spectrum of
tumours remains unclear.
One important feature of all the above studies in Li-Fraumeni
cells is that they are extremely sensitive to DNA damage of any
sort. This has considerable implications for the clinical manage-
ment ofpatients in Li-Fraumeni families, particularly in screening
for cancers and for treatment. While the frequency of radiation-
induced tumours is still not known in germline mutant TP53
carriers, there is evidence that second malignant neoplasms occur
at a relatively high frequency in the radiation zone (Strong and
Williams, 1987; Heyn et al, 1993), although more extensive
studies must be carried out to confirm this. The relative contribu-
tions of genetic background and radiation remain to be evaluated
in a careful epidemiological study.
ANIMAL MODELS OF LI-FRAUMENI SYNDROME
The earliest study in which a TP53-transgenic mouse was gener-
ated was described in 1989 (Lavigueur et al, 1989), before the
genetic basis of LFS was elucidated. The observed occurrence of
multiple tumours in the transgenic strains, including tumours
typical of LFS, contributed towards the decision to study TP53 as
a candidate gene by Malkin et al (1990). These transgenic mice
carried their normal wild-type TP53 alleles as well as high
numbers of copies of a mutant transgene, and tumours developed
in 20% ofthe transgenic mice, commonly osteosarcomas and lung
adenocarcinomas but also lymphomas and a range of other
tumours. Interestingly, the levels ofexpression ofthe mutant trans-
genes did not correlate simply with the sites oftumour formation.
Donehower et al (1992) reported the generation of transgenic
knockout mouse strains that were homozygous null for TP53, with
part of intron 4 and exon 5 replaced with a neo gene. These mice
were, surprisingly, viable and initially appeared to have no devel-
opmental abnormalities. Three-quarters of the homozygous null
mice developed tumours by 6 months of age, predominantly
lymphoblastic lymphomas but also sarcomas. The same group
(Harvey et al, 1993) extended these studies to examine heterozy-
gous null/wild-type mice, which reflects more accurately the
situation in some LFS families. In contrast to the situation in
homozygous null mice in which 100% had developed tumours or
died by 10 months of age, only 50% of heterozygotes had devel-
oped tumours by the age of 18 months. The spectrum of tumours
differed between the two groups, with 58% of the heterozygotes
developing sarcomas (predominantly osteosarcomas) and only
32% developing lymphomas (Harvey et al, 1993), but this animal
model is still not a perfect LFS paradigm, as brain and mammary
tumours are very rarely seen. The heterozygotes showed consider-
ably increased susceptibility to dimethylnitrosamine carcino-
genesis compared with wild-type mice. Loss of heterozygosity
was seen in only 55% oftumours, although the retained allele had
not been sequenced in those tumours showing no LOH. This
frequency is close to that seen in tumours ofpatients with germline
TP53 mutations (see above and Varley et al, 1997b). Using a
different disrupted TP53 gene in which 40% of the gene had been
replaced, Jacks et al (1994) reported essentially identical results
to Donehower's group. Subsequently two groups reported that
homozygous null mice do not develop normally, with up to 30%
of female embryos showing abnormal neural tube closure and
exencephaly (Armstrong et al, 1995; Sah et al, 1995).
TP53-deficient mice are extremely sensitive to gamma irradia-
tion with a reduced tumour latency following low-level irradiation
(Kemp et al, 1994). This sensitivity is associated with an increase
in radiation-induced double-strand chromosomal breaks (Lee et al,
1994). Transgenic mice carrying mutant TP53 genes show cellular
radioresistance in haematopoietic cells (Lee and Bernstein, 1993).
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At least two studies have used a lacItransgene as a target to deter-
mine the mutation rate in wild-type and homozygous null mice.
Neither study has been able to demonstrate an increased mutation
frequency, either spontaneously or after treatment with DNA-
damaging agents (Nishino et al, 1995; Sands et al, 1995).
In many respects the transgenic and TP53-deficient mice are
good models for Li-Fraumeni syndrome. However none of the
mouse strains generated to date is a perfect model, particularly
with respect to the spectrum oftumours seen in these animals. The
targeted introduction of a specific point mutation into one allele in
a heterozygous mouse would be of great interest.
CLINICAL ASPECTS OF LI-FRAUMENI FAMILIES
The definition of classic LFS, like the Amsterdam criteria for
HNPCC (B Liu et al, 1996), seems to be agoodpredictorfor muta-
tions in the causative genes TP53 and the HNPCC mismatchrepair
genes respectively. The definition is therefore useful in genetic
counselling as it allows the counsellor to talk in purely Mendelian
terms. In our series (Varley et al, 1997a), TP53 mutations have
been detected in 71% of families with classic LFS, and it is
possible that ahighproportion offamilies with no detectable TP53
mutation have functional loss. Our data, together with those of
other groups (Sameshima et al, 1992; Wagner et al, 1994; Diller
et al, 1995), suggest that the chance of finding a germline TP53
mutation in a family with LFS increases if the family includes a
case of ACC and/or rhabdomyosarcoma diagnosed in early child-
hood. This allows the clinician to talk with reasonable certainty
about the possibility ofpredictive tests in thefamily. Even in fami-
lies excluded from TP53 by linkage, another dominant gene is
likely; therefore it is reasonable to talk of50% risk oftransmission
of a highly penetrant cancer-predisposing gene with a high risk of
childhood and early adult malignancy. In LFS families, the risk of
childhood tumours is estimated to be in the order of 20%, with
50% developing cancer by 40 years and 90% by 60 years of age
(Lustbader et al, 1992).
LFL families are more difficult. Using our own definition
(Birch et al, 1994a), under 25% will have a detectable TP53 muta-
tion. Aproportion may be due to other genes, but some may be due
to chance association. It is not possible, therefore, to counsel in
terms of a 50% risk for relatives of affected cases or to make firm
predictions about the likely tumour spectrum for at-risk individ-
uals. Some of these family aggregates may be due to a recent new
mutation and some latitude with the criteria, particularly if the
family includes childhood ACC or rhabdomyosarcoma, may well
predict a high proportion ofthe TP53-positive LFL families. Once
a mutation has been detected genetic counselling becomes
straightforward, but the absence of a mutation does not allow
complete reassurance.
In common with current practice in breast cancer families,
predictive presymptomatic testing should not be offered to at-risk
individuals unless a TP53 mutation has already been identified in
an affected individual. Although mutations can be found in DNA
extracted from paraffin-embedded tumour material, the DNA is
often of poor quality. The DNA may fail to amplify certain exons
of TP53 and, if non-sequencing mutation detection methods are
used, certain mutations can be missed (see Varley et al, 1995).
Tumours may also of course contain a somatic mutation and this
possibility would have to be excluded by finding the identical
mutation in multiple tumours from the same orrelated individuals.
Only ifthe mutation was confirmed in this way could it be used in
predictive testing. In practice, therefore, it is usually necessary to
have a living affected individual on whom to undertake mutation
analysis. As described above, 26% of mutations occur outside the
accepted hotspots, and therefore the whole gene needs to be
sequenced in each case. Mutations that truncate the protein or that
are accepted as affecting key properties of TP53 from functional
studies, or their presence either in other Li-Fraumeni families or
commonly in human tumours, can be used in predictive testing.
However predictive testing using missense or splice-site mutations
outside the above categories should be undertaken with extreme
caution. Even ifother affectedfamily members test positive forthe
same sequence variant, this could still represent a rare polymor-
phism and, if possible, some functional studies should be carried
out to determine relevance of the alteration. However, if many
affected family members are positive for the 'mutation' and,
especially if there is loss of the wild-type allele in tumour tissue,
then testing would be reasonable.
Our own early experience and that of others (Schneider et al,
1995) would suggest that uptake of testing will be relatively low.
Once an individual is availed ofthe risks to a mutation carrier and
the paucity of options with regard to early detection and preven-
tion, they may prefer to live with the better-than-even chance that
they will not carry the mutation. (Their 50% risk will have been
reduced, assuming they have reached adulthood by the time of
counselling.) Nonetheless a significant minority proceed to testing
and will require extra support both psychologically and in terms of
extra surveillance if they test positive. It is vital that individuals
are given adequate time for reflection before taking the test and
therefore testing protocols should be similar to those adopted for
Huntington's disease (Li et al, 1992; Eeles, 1993; Birch, 1994). It
is widely accepted that testing of children should not be offered
routinely; however, parents may exert considerably pressure to
have a child tested. Each case should be treated on its own merits.
If the case can be answered that the child is likely to benefit from
the test, then after very careful counselling that includes the child
or children, proceeding to testing may be appropriate in some
isolated cases. We have been involved in tests on four children
over 10 years of age, one of whom was mutation positive.
Although follow-up is still early, all the children and families seem
to have benefited from testing. Nonetheless, long-term effects
such as insurance and other discrimination on TP53-positive
individuals may deter most genetic counsellors and parents from
testing children.
Given the wide diversity and unpredictability of tumours in
Li-Fraumeni syndrome, no widely accepted screening procedure
has been devised. It may be wise to avoid as far as possible any
radiological screening that exposes the patient to excessive
ionizing radiation. However one of the few organs that could be
targeted for screening, i.e. the breast (Li et al, 1992), does not have
another proven screening test. Ultrasound is very operator depen-
dent and has poor sensitivity, while magnetic resonance imaging
(MRI) is only now being evaluated. Mammography would have to
be undertaken annually from 20 years if it were to be used and,
while very little radiation passes beyond the skin, concern must be
voiced aboutthe possibility ofinducing a tumourthat would other-
wise not have occurred.
While there is no proven way of detecting tumours early in
Li-Fraumeni syndrome, it is vital that individuals at risk have
access to informed clinicians and that early symptoms are rigor-
ously investigated. We offer an annual clinical review to all at-risk
individuals and, in addition, we offer annual abdominal ultrasound
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and full blood count to children and a specialist breast examination
with or without ultrasound to women over 20 years. Selective
screening, such as cranial MRI in families with brain tumours or
gastroscopy in families with gastric carcinoma, could also bejusti-
fied, although their effectiveness is not known.
Some women in LFS families have undertaken preventative
mastectomy (DGRE, unpublished data). However this does not
allow the same level of reassurance as in BRCAJ and BRCA2
carriers as so many other organs are at risk. Families are therefore
pinning a great deal of hope on genetic therapies. Germline gene
therapy, even if it were possible, has not been approved by any
regulatory authority. Even selective/tissue-specific targeting of
treatment is still beyond our current capabilities. Nonetheless, the
outcome of many clinical trials involving the manipulation of
TP53 is eagerly awaited. This will probably have more implica-
tions for treatment of tumours than in prevention, but any proce-
dure reducing mortality in Li-Fraumeni syndrome would be
gratefully accepted by the families. There is a general assumption
that tumours in carriers of germline TP53 mutations may be rela-
tively radiation resistant, although hard data are not available and
there appears to be a high risk of second malignancy in the radia-
tion field (Strong and Williams, 1987; Heyn et al, 1993). However,
more extensive longitudinal studies on germline TP53 mutation
carriers are necessary to assess the effectiveness of current treat-
ment regimens.
It should be stressed that counselling, genetic testing and
screening for early detection of cancers in Li-Fraumeni families
are in their infancy. Although some data are available on age-
specific risks of cancers associated with Li-Fraumeni syndrome,
at present the estimated risks are based on very small numbers of
cancer-affected individuals. Furthermore, families in whom TP53
mutation analysis has been undertaken were selected because of
their striking patterns of cancer. In the circumstances, it is recom-
mended that any such counselling, testing and screening should
only be undertaken in centres experienced with both clinical
aspects ofthe syndrome and with expertise in sequence analysis of
the entire TP53 gene. Of equal importance, families in whom
TP53 mutation analysis is undertaken should be included in a
research programme encompassing molecular genetic, genetic
epidemiological, clinical and psychosocial aspects. It is only by
applying such a systematic approach and with international
collaboration that progress will be made.
CONCLUDING COMMENTS
Although families conforming to the strict definitions of classic
LFS or LFL are very rare, germline TP53 mutations may be rela-
tively common in certain groups ofcancer patients. The definition
ofclassic LFS is still ofgreat value in clinical practice and predic-
tive testing but may need to be modified to take into account the
occurrence of tumours such as adrenocortical carcinomas. In view
ofthe potentially damaging effects ofradiation on cells with TP53
mutations, considerable care should be taken when screening
patients with germline mutations for tumours, and the design and
implementation of novel screening protocols is of some urgency.
Studies of cells from patients with germline mutations have
provided, and will continue to provide, insight into the function(s)
of TP53, and further characterization of families with no
detectable coding mutation may identify germline mutations in
other genes involved in the same pathway(s).
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